公开(公告)号：US20240050561A1

公开(公告)日：2024-02-15

申请号：US18269284

申请日：2021-10-16

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher Bradford FOX

IPC: A61K39/39 ,  A61K39/145 ,  A61K47/22 ,  A61K9/107 ,  A61P37/04

CPC classification number: A61K39/39 ,  A61K39/145 ,  A61K47/22 ,  A61K9/1075 ,  A61P37/04 ,  A61K2039/55566

Abstract: This disclosure describes the use of solanesol as an adjuvant in vaccine compositions, as well as related prophylactic and therapeutic methods. Solanesol may be used to replace squalene in vaccine compositions with similar or superior immunostimulatory effects. Solanesol, which is solid at room temperature, may be formulated for use in vaccine compositions by heating above its melting temperature in an aqueous solution to form a dispersion.

公开(公告)号：US20230381292A1

公开(公告)日：2023-11-30

申请号：US18190934

申请日：2023-03-27

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Steven G. REED ,  Malcolm S. DUTHIE

IPC: A61K39/04 ,  A61K39/39

CPC classification number: A61K39/04 ,  A61K39/39 ,  A61K2039/55561

Abstract: Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.

公开(公告)号：US20230338501A1

公开(公告)日：2023-10-26

申请号：US18024703

申请日：2021-07-04

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Neal VAN HOEVEN ,  Emily VOIGT

IPC: A61K39/12 ,  C12N7/00 ,  A61P31/14 ,  A61K9/107

CPC classification number: A61K39/12 ,  C12N7/00 ,  A61P31/14 ,  A61K9/1075 ,  A61K2039/53

Abstract: This disclosure provides ribonucleic acid (RNA) polynucleotides encoding replication-competent viral genomes that, when introduced to a subject, induce an active viral replication. The RNA may be provided naked or with an artificial RNA delivery system. The viral genome may be a full-length genome of an attenuated viral strain. For example, the RNA may encode an attenuated Chikungunya or yellow fever virus. The artificial RNA delivery system may be a lipid particle such as a lipid nanoparticle (LNP), a nanostructure lipid carrier (NLC), or a cationic nanoemulsion (CNE). This disclosure also provides methods of inducing an immune response, including protective immunity, by administering to a subject an RNA polynucleotide that encodes a replication-competent viral genome in an amount sufficient to cause viral replication in the subject. The immune response may include inducing the production of neutralizing antibodies at a level comparable to inoculation with a live-attenuated virus.

公开(公告)号：US20230310569A1

公开(公告)日：2023-10-05

申请号：US18024727

申请日：2021-07-04

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Emily VOIGT

IPC: A61K39/12 ,  A61K39/39

CPC classification number: A61K39/12 ,  A61K39/39 ,  A61K2039/53

Abstract: The present application discloses a genetically-adjuvanted RNA vaccine including one or more genes encoding immune stimulatory adjuvants in the genetic material of the vaccine backbone. The vaccine may be applied to enhance the magnitude, diversity, and durability of RNA vaccine-stimulated immunity in a subject.

公开(公告)号：US20230310323A1

公开(公告)日：2023-10-05

申请号：US18024733

申请日：2021-07-02

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Ryan M. KRAMER ,  Emily VOIGHT ,  Alana GERHARDT ,  Michelle ARCHER

IPC: A61K9/19 ,  A61K9/107 ,  A61K39/12

CPC classification number: A61K9/19 ,  A61K9/1075 ,  A61K39/12 ,  A61K2039/55555

Abstract: This disclosure provides thermostable, lyophilized compositions of nano structured lipid carrier (NLC) particles, methods of making the compositions, and methods of using the compositions for stimulating an immune response. The lyophilized compositions are in the form of cakes that form oil-in-water emulsions upon reconstitution. The compositions comprise NLC particles lyophilized in the presence of a cake-forming excipient. The compositions may be lyophilized with a bioactive agent, or the bioactive agent may be added after reconstitution. The bioactive agent may be RNA that encodes an antigen such as a viral protein. The thermostable, lyophilized compositions have uses as vaccine platforms or vaccines. The lyophilized cake maintains shape, structure, and color for at least 21 months stored at room temperature. Integrity and activity of the bioactive agent is maintained for at least eight months at room temperature and at least 21 months refrigerated.

公开(公告)号：US20220280640A1

公开(公告)日：2022-09-08

申请号：US17731671

申请日：2022-04-28

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher B. FOX

IPC: A61K39/39 ,  A61K35/76 ,  A61K39/04 ,  A61K39/12 ,  A61K45/06 ,  A61P31/06 ,  A61P31/12 ,  A61P33/04 ,  A61P35/00 ,  C07K14/705

Abstract: Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.

公开(公告)号：US12061160B2

公开(公告)日：2024-08-13

申请号：US18170114

申请日：2023-02-16

Applicant: UNIVERSITY OF MARYLAND, BALTIMORE ,  ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Yihua (Bruce) Yu ,  Marc Taraban ,  Christopher Fox

IPC: G01N24/08 ,  G01N33/15

CPC classification number: G01N24/082 ,  G01N33/15

Abstract: A method of using the transverse relaxation rate (R2) of solvent NMR signal to noninvasively assess if an alum-containing product, such as a vaccine, has been acceptably resuspended for use following transport and/or storage. This technique allows for the manufacturer and/or distributor and/or end user to monitor for unexpected stressors associated with transport and/or storage including, but not limited to, temperature fluctuations, pH changes, vigorous shaking during transportation, exposure to sunlight, and freezing.

公开(公告)号：US11897922B2

公开(公告)日：2024-02-13

申请号：US17367812

申请日：2021-07-06

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Steven G. Reed ,  Rhea N. Coler ,  Gregory C. Ireton ,  Sylvie Bertholet

IPC: C07K14/35 ,  A61K39/04 ,  C07K14/285 ,  G01N33/569 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K14/35 ,  A61K39/04 ,  C07K14/285 ,  G01N33/5695 ,  G01N33/68 ,  A61K2039/55561 ,  C07K2319/00 ,  G01N2469/20 ,  Y02A50/30

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp.) antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

公开(公告)号：US11801223B2

公开(公告)日：2023-10-31

申请号：US15108773

申请日：2014-12-29

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher B. Fox ,  Thomas Vedvick ,  Lucien Barnes V. ,  Ryan M. Kramer ,  Steven G. Reed

IPC: A61K9/19 ,  A61K39/00 ,  A61K47/26 ,  A61K39/04 ,  A61K39/39 ,  A61K47/22 ,  A61K47/10

CPC classification number: A61K9/19 ,  A61K39/00 ,  A61K39/04 ,  A61K39/39 ,  A61K47/10 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/55572

Abstract: The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient.

公开(公告)号：US11510875B2

公开(公告)日：2022-11-29

申请号：US14377488

申请日：2013-02-07

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher Fox ,  Steven G. Reed ,  Susan Baldwin ,  Thomas Vedvick

IPC: A61K9/113 ,  A61K39/39 ,  A61K39/015 ,  A61K39/12 ,  A61K9/107 ,  A61K47/06 ,  A61K39/00 ,  A61K47/24 ,  A61K47/26

Abstract: Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.